BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. 2005

Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Republic of Korea.

The pharmacokinetics of DA-8159 and one of its metabolites, DA-8164, were compared after intravenous and oral administration of DA-8159 at a dose of 30 mg/kg to spontaneously hypertensive rats (SHRs) at 16 and 6 weeks old and their respective age-matched control normotensive Kyoto-Wistar rats (KW rats), and deoxycorticosterone acetate-salt-induced hypertensive rats (DOCA-salt rats) at 16 weeks old and their age-matched control Sprague-Dawley rats. After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml). However, the AUC values of both DA-8159 and DA-8164 were not significantly different between the 6-week-old SHRs and their control rats. The above AUC differences in 16-week-old SHRs may be due to neither hereditary characteristics of SHRs nor the hypertensive state itself.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance

Related Publications

Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin.
September 2004, Journal of pharmaceutical sciences,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats.
June 1999, Drug metabolism and disposition: the biological fate of chemicals,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats.
April 2006, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats.
August 1993, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.
April 1994, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetics of a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.
November 2000, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
DOCA-salt induced malignant hypertension in spontaneously hypertensive rats.
February 1984, Journal of hypertension,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, in spontaneously or DOCA-salt-induced hypertensive rats.
January 2011, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Effects of omeprazole or cola beverage on the pharmacokinetics of oral DA-8159, a new erectogenic, in rats.
December 2005, Biopharmaceutics & drug disposition,
Yu C Kim, and Hyun J Shim, and Joo H Lee, and Dong S Kim, and Jong W Kwon, and Won B Kim, and Inchul Lee, and Myung G Lee
Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2.
April 2008, British journal of pharmacology,
Copied contents to your clipboard!